Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Biotheryx, Inc.

Irit Snir-Alkalay

Joseph P Vacca

Dansu Li

Yinon Ben-Neriah

Guy Brachya

Ido Burstain

Waleed Minzel

Yinon Ben Neriah

Avanthika Venkatachalam

Provided herein are heteroaryl compounds, for example, a compound of Formula I or IA, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, ameliorating, or preventing one or more symptoms of a disorder, disease, or condition mediated by a casein kinase 1 (CK1), an interleukin-1 receptor associated kinase (IRAK1), or a cyclin-dependent kinase 9 (CDK9).

Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use

The present invention provides pyrazole derivatives, e.g., a compound of Formula (I), and their uses in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.

Pyrazole compounds and uses thereof

The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.

Pyrazole pyrimidine derivative and uses thereof

The present invention provides pyrazole derivatives of Formula (I), and in particular N1-(4-(5-(cyclopropylmethyl)-1-methyl-1H-pyrazol-4-yl) pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as casein kinase 1 (CK1) and/or interleukin 1 receptor associated kinase 1 (IRAKI) inhibitors for treating cancer, inflammatory and immune related disorders. 

Growing community of inventors

Mevasseret Zion, Israel

Irit Snir-Alkalay